{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:31:22Z","timestamp":1777419082209,"version":"3.51.4"},"reference-count":38,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2012,9,18]],"date-time":"2012-09-18T00:00:00Z","timestamp":1347926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2012,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To evaluate the safety, efficacy, pharmacokinetics, pharmacodynamic properties, and clinical application of ezogabine (retigabine. INN), an antiepileptic drug approved in 2011.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>Published data from in vitro, animal, and clinical studies were obtained from PubMed and CINAHL searches, from January 1980 to March 31, 2012. Other relevant data regarding the safety and efficacy of ezogabine were obtained from the Food and Drug Administration and the European Medication Agency Web sites.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>Selected articles were prospective in vitro, animal, and controlled clinical studies of ezogabine. Non-English-language articles were excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>In vitro and animal studies show that ezogabine activates voltage-gated potassium channels, leading to reduction of seizure frequency by inhibiting hyperexcitability activity in the central nervous system. Additionally, ezogabine enhances \u03b3-aminobutyric acid (GABA) activity and de novo GABA synthesis. Eight clinical studies of ezogabine have been published, 5 being Phase 1 clinical trials in healthy subjects and 3 being Phase 3 clinical trials in patients with pharmacoresistant partial-onset seizures. Phase 3 clinical trials demonstrated the safety and efficacy of ezogabine in patients with partial-onset seizures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Clinical trials have shown that ezogabine is efficacious as an adjunctive agent in patients with pharmacoresistant partial seizures. Careful monitoring of drug interactions and adverse reactions is necessary. While ezogabine is efficacious (or partial seizures, its precise role in the management of patients with epilepsy is yet to be determined.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1r153","type":"journal-article","created":{"date-parts":[[2012,9,19]],"date-time":"2012-09-19T04:22:10Z","timestamp":1348028530000},"page":"1358-1367","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Ezogabine: An Evaluation of Its Efficacy and Safety as Adjunctive Therapy for Partial-Onset Seizures in Adults"],"prefix":"10.1177","volume":"46","author":[{"given":"Mikiko","family":"Yamada","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, School of Pharmacy, University of Kansas, Kansas City"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy E","family":"Welty","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, School of Pharmacy, University of Kansas"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2012,9,18]]},"reference":[{"key":"bibr1-aph.1R153","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200002033420503"},{"key":"bibr2-aph.1R153","unstructured":"EMEA\/Committee for Proprietary Medicinal Products. Note for guidance on clinical investigation of medicinal products in the treatment of epileptic disorders. In: EMEA\/CPMP, ed. London, UK: EMEA\/Committee for Proprietary Medicinal Products, 2000: 1\u201312."},{"key":"bibr3-aph.1R153","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.63.10_suppl_4.S3"},{"key":"bibr4-aph.1R153","unstructured":"European Medicines Agency. Trobalt: EPAR\u2014summary for the public. www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/001245\/human_med_001431.jsp&murl=menus\/medicines\/medicines.jsp&mid=WC0b01ac058001d124 (accessed 2011 Jun 20)."},{"key":"bibr5-aph.1R153","unstructured":"Food and Drag Administration. FDA approves Potiga to treat seizures in adults. www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm258834.htm (accessed 2011 Jun 13)."},{"key":"bibr6-aph.1R153","unstructured":"Food and Drug Administration Center for Drug Evaluation and Research. Printed labeling, www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/022345Orig1s000TOC.cfm (accessed 2011 Nov 16)."},{"key":"bibr7-aph.1R153","first-page":"49","author":"Edlund W","year":"2005","journal-title":"Definition for classification of evidence. Clinical practice guideline process manual 2004 edition"},{"key":"bibr8-aph.1R153","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(95)00050-X"},{"key":"bibr9-aph.1R153","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(96)00073-8"},{"key":"bibr10-aph.1R153","doi-asserted-by":"publisher","DOI":"10.1124\/mol.58.3.591"},{"key":"bibr11-aph.1R153","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-200408000-00024"},{"key":"bibr12-aph.1R153","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3458.2005.tb00033.x"},{"key":"bibr13-aph.1R153","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(95)00101-8"},{"key":"bibr14-aph.1R153","doi-asserted-by":"publisher","DOI":"10.1007\/s00424-010-0831-3"},{"key":"bibr15-aph.1R153","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2008.150656"},{"key":"bibr16-aph.1R153","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(00)00866-1"},{"key":"bibr17-aph.1R153","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(94)00077-A"},{"key":"bibr18-aph.1R153","first-page":"1063","volume":"50","author":"Rundfeldt C","year":"2000","journal-title":"Arzneimittelforschung"},{"key":"bibr19-aph.1R153","unstructured":"Food and Drug Administration Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s). www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/022345Orig1s000TOC.cfm (accessed 2011 Nov 15)."},{"key":"bibr20-aph.1R153","doi-asserted-by":"publisher","DOI":"10.1177\/00912700222011210"},{"key":"bibr21-aph.1R153","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0090-9556(24)15258-0","volume":"27","author":"Hempel R","year":"1999","journal-title":"Drag Metab Dispos"},{"key":"bibr22-aph.1R153","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0090-9556(24)15257-9","volume":"27","author":"Hiller A","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"bibr23-aph.1R153","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01825.x"},{"key":"bibr24-aph.1R153","doi-asserted-by":"publisher","DOI":"10.1038\/sj.tpj.6500359"},{"key":"bibr25-aph.1R153","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2003.12"},{"key":"bibr26-aph.1R153","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-003-0558-6"},{"key":"bibr27-aph.1R153","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000259034.45049.00"},{"key":"bibr28-aph.1R153","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182194bd3"},{"key":"bibr29-aph.1R153","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181fd6170"},{"key":"bibr30-aph.1R153","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.00992.x"},{"key":"bibr31-aph.1R153","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2009.02496.x"},{"key":"bibr32-aph.1R153","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000334751.89859.7f"},{"key":"bibr33-aph.1R153","unstructured":"European Medicines Agency. Annex I summary of product characteristics. www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/001245\/human_med_001431.jsp&murl=menus\/medicines\/medicines.jsp&mid=WC0b01ac058001d124&jsenabled=true (accessed 2011 Jun 20)."},{"key":"bibr34-aph.1R153","unstructured":"Food and Drug Administration Center for Drug Evaluation and Research. Risk assessment and risk mitigation review(s). www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/022345Orig1s000TOC.cfm (accessed 2011 Nov 16)."},{"key":"bibr35-aph.1R153","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000138155.33749.f4"},{"key":"bibr36-aph.1R153","unstructured":"Food and Drug Administration Center for Drug Evaluation and Research. Medical review, www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/022345Orig1s000TOC.cfm (accessed 2011 Jan 8)."},{"key":"bibr37-aph.1R153","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1M141"},{"key":"bibr38-aph.1R153","unstructured":"Food and Drug Administration. Major human transporters. www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/DevelopmentResources\/DrugInteractionsLabeling\/ucm093664.htm#classInhibit (accessed 2012 Apr 2)."}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1R153","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1R153","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:09:17Z","timestamp":1777374557000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1R153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,18]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["10.1345\/aph.1R153"],"URL":"https:\/\/doi.org\/10.1345\/aph.1r153","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,18]]}}}